11.13.14
Wayne, Pa.-based Intact Vascular Inc. has hired Bryan A. Claseman as its new vice president of marketing and business development and Marc Penna as vice president of clinical affairs.
“Bryan and Marc bring us depth of experience and a combination of marketing and clinical research skills that position us for great success as we move forward with the development of our Tack Endovascular System,” said CEO Bruce Shook.
Claseman joins the company from Preventice, where he was vice president of marketing. He brings more than 30 years of medical device experience with a decade each in vascular, orthopedic, and urology markets. He has held senior management and executive marketing, business development, and information technology positions at several early-stage companies including Cardiovascular Systems Inc., Surmodics Inc., and IntraTherapeutics Inc., and several multinational companies (Zimmer Holdings Inc., Boston Scientific Corp., Pfizer Inc., Schneider Worldwide and American Medical Systems).
Penna joins the company from Angiodynamics where he was senior director of clinical and medical affairs. He has more than 10 years of experience in the medical device industry managing all phases of clinical research including pre-clinical, pivotal and post-market clinical trials. He has held positions at Edwards Lifesciences Corporation, where he managed large-scale transcatheter aortic valve replacement pivotal trials, and at Boston Scientific, where he worked on drug-eluting stents. Penna has spent the majority of his career working in the cardiovascular, endovascular and oncology therapeutic areas.
“Intact Vascular is addressing an unmet need in endovascular therapy and I am thrilled to become part of the team that will drive this innovation forward,” said Penna. “The company has made a considerable investment in clinical research and I look forward to building upon that foundation.”
Intact Vascular makes minimally invasive peripheral vascular products.
“Bryan and Marc bring us depth of experience and a combination of marketing and clinical research skills that position us for great success as we move forward with the development of our Tack Endovascular System,” said CEO Bruce Shook.
Claseman joins the company from Preventice, where he was vice president of marketing. He brings more than 30 years of medical device experience with a decade each in vascular, orthopedic, and urology markets. He has held senior management and executive marketing, business development, and information technology positions at several early-stage companies including Cardiovascular Systems Inc., Surmodics Inc., and IntraTherapeutics Inc., and several multinational companies (Zimmer Holdings Inc., Boston Scientific Corp., Pfizer Inc., Schneider Worldwide and American Medical Systems).
Penna joins the company from Angiodynamics where he was senior director of clinical and medical affairs. He has more than 10 years of experience in the medical device industry managing all phases of clinical research including pre-clinical, pivotal and post-market clinical trials. He has held positions at Edwards Lifesciences Corporation, where he managed large-scale transcatheter aortic valve replacement pivotal trials, and at Boston Scientific, where he worked on drug-eluting stents. Penna has spent the majority of his career working in the cardiovascular, endovascular and oncology therapeutic areas.
“Intact Vascular is addressing an unmet need in endovascular therapy and I am thrilled to become part of the team that will drive this innovation forward,” said Penna. “The company has made a considerable investment in clinical research and I look forward to building upon that foundation.”
Intact Vascular makes minimally invasive peripheral vascular products.